September 1, 2006EP Europace669 citationsOpen Access

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society

VFValentı́n Fuster LRLars Rydén DCD.S. Cannom

Key Result

The 2006 ACC/AHA/ESC atrial fibrillation guidelines classify digoxin, procainamide, quinidine, verapamil, and diltiazem as drugs with unproven efficacy or no longer recommended.

Structured PICO

Population

Patients with atrial fibrillation

Intervention

Management strategies including antiarrhythmic drugs

Provides the 2006 ACC/AHA/ESC clinical practice guidelines for the management of patients with atrial fibrillation.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

.2. Drugs with unproven efficacy or no longer recommended . . 8.1.6.2.1. Digoxin . . . . . . . 8.1.6.2.2. Procainamide . . . . 8.1.6.2.3. Quinidine . . . . . . 8.1.6.2.4. Verapamil and diltiazem . . . . . . 8.1.7. Out-of-hospital initiation of antiarrhythmic drugs in patients with atrial fibrillation . . . . . .

问 AI

Bookmark

View Full Paper

问 AI

Bookmark

View Full Paper

Cite This Study

Fuster et al. (Fri,) reported a other. The 2006 ACC/AHA/ESC atrial fibrillation guidelines classify digoxin, procainamide, quinidine, verapamil, and diltiazem as drugs with unproven efficacy or no longer recommended.

synapsesocial.com/papers/6a6273b6cd947529a989d1f3 https://doi.org/https://doi.org/10.1093/europace/eul097